Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.lupin.com | |
Market Cap | 28,847.32 Cr. | |
Enterprise Value(EV) | 31,593.35 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -33.62 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
Industry PE | 28.47 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 267.40 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 2.37 | Calculated using Price: 634.70 |
Dividend Yield | 0.63 | Period Ending 2021-03 |
No. of Shares Subscribed | 45.45 Cr. | 454,503,188 Shares |
FaceValue | 2 | |
Company Profile | ||
Lupin was founded on the auspicious ‘Guddi padwa’ Day in 1968 by Dr. Desh Bandhu Gupta - a visionary with a compelling mission to create a better world for people. DBG as he was fondly called, started the company with a dream - a dream to fight life-threatening, infectious diseases with affordable and high-quality drugs of the highest social priority. With his vision, inimitable commitment and passion, Dr. Gupta steered the organization to become one of the fastest-growing Generic pharmaceutical companies around the world.The name ‘Lupin’ was inspired by the flower Lupin which is known to nourish the soil it grows in. The Lupin flower is also known to be tolerant of the infertile soils and capable of pioneering change in barren and poor climates. This inspiration is at the core of the company’s ethos as it relentlessly strives to build medical solutions to meet the unmet needs of the society not just for a few but for the many across the globe. Lupin is recognised as one of the world's largest manufacturers of Tuberculosis drugs. The company have significant market share across multiple therapy areas such as Cardiovascular (prils and statins), Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). To add to this, the company has proud to maintain over the years its global leadership positions in other therapy areas such as Anti-TB and Cephalosporin. Business area of the company Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. Products and services offered by the company
Awards
Milestones
|
1 Day |
|
+0.40% |
1 Week |
|
-8.47% |
1 Month |
|
-17.99% |
3 Month |
|
-16.98% |
6 Month |
|
-29.08% |
1 Year |
|
-47.07% |
2 Year |
|
-27.00% |
5 Year |
|
-51.65% |
10 Year |
|
+18.97% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 29.12 | 30.89 | 31.09 | 22.80 | 20.98 | 1.91 | 4.55 | -2.12 | 9.46 | |
Return on Capital Employed (%) | 32.70 | 40.97 | 40.30 | 24.38 | 18.53 | 3.54 | 8.45 | 6.02 | 9.70 | |
Return on Assets (%) | 15.98 | 19.70 | 21.08 | 12.82 | 10.57 | 0.99 | 2.32 | -1.05 | 5.09 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 5,204 | 6,932 | 8,874 | 11,163 | 13,498 | 13,577 | 13,742 | 12,537 | 13,803 | 12,153 | |
Non Curr. Liab. | 573 | 507 | 426 | 6,032 | 6,447 | 6,876 | 7,296 | 3,003 | 1,136 | 1,153 | |
Curr. Liab. | 3,007 | 2,630 | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,276 | |
Minority Int. | 59 | 67 | 24 | 32 | 35 | 40 | 47 | 44 | 55 | 69 | |
Equity & Liab. | 8,843 | 10,135 | 13,054 | 22,289 | 26,100 | 25,589 | 27,215 | 24,810 | 23,430 | 21,651 | |
Non Curr. Assets | 3,700 | 4,035 | 5,221 | 12,402 | 14,147 | 13,379 | 13,362 | 9,396 | 9,444 | 9,194 | |
Curr. Assets | 5,143 | 6,100 | 7,832 | 9,887 | 11,953 | 12,210 | 13,854 | 15,413 | 13,986 | 12,458 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 8,843 | 10,135 | 13,054 | 22,289 | 26,100 | 25,589 | 27,215 | 24,810 | 23,430 | 21,651 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 9,641 | 11,287 | 12,770 | 14,139 | 17,494 | 15,804 | 16,751 | 16,837 | 15,163 | 16,405 | |
Other Income | 28 | 116 | 240 | 185 | 107 | 150 | 333 | 484 | 136 | 229 | |
Total Income | 9,669 | 11,403 | 13,010 | 14,324 | 17,601 | 15,955 | 17,084 | 17,320 | 15,299 | 16,634 | |
Total Expenditure | -7,371 | -8,284 | -9,150 | -10,454 | -13,001 | -12,657 | -14,082 | -14,362 | -12,596 | -16,205 | |
PBIDT | 2,298 | 3,119 | 3,859 | 3,871 | 4,600 | 3,298 | 3,002 | 2,958 | 2,703 | 429 | |
Interest | -41 | -27 | -10 | -59 | -153 | -204 | -302 | -363 | -141 | -143 | |
Depreciation | -332 | -261 | -435 | -487 | -912 | -1,086 | -846 | -970 | -887 | -1,659 | |
Taxation | -584 | -962 | -970 | -1,059 | -979 | -288 | -902 | -1,147 | -449 | -137 | |
Exceptional Items | -1,464 | -340 | -752 | ||||||||
PAT | 1,340 | 1,870 | 2,444 | 2,265 | 2,556 | 255 | 612 | -274 | 1,227 | -1,510 | |
Minority Interest | -26 | -33 | -41 | -9 | -7 | -7 | -19 | ||||
Share Associate | 5 | 8 | 4 | -5 | 4 | -10 | 0 | ||||
Other Related Items | |||||||||||
Consolidated Net Profit | 1,314 | 1,836 | 2,403 | 2,261 | 2,557 | 251 | 607 | -269 | 1,217 | -1,528 | |
Adjusted EPS | 29 | 41 | 53 | 50 | 57 | 6 | 13 | -6 | 27 | -34 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 560 | 1,251 | 2,004 | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | |
Cash Fr. Inv. | -741 | -522 | -859 | -1,055 | -6,962 | -2,527 | 470 | -3,282 | 1,107 | -1,240 | |
Cash Fr. Finan. | 109 | -663 | -857 | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | |
Net Change | -72 | 66 | 288 | 1,482 | -1,508 | 2,019 | 729 | -872 | 1,685 | -1,303 | |
Cash & Cash Eqvt | 245 | 311 | 607 | 2,108 | 780 | 2,799 | 1,416 | 544 | 2,229 | 926 |
Thu, 19 May 2022
Financial Result Updates
|
|
Thu, 19 May 2022
Investor Presentation
|
|
Thu, 19 May 2022
Press Release
|
Thu, 19 May 2022 |
|
|
|
|
|